GlobeNewsWire
16 Jun 2026, 08:52 UTC · 13w ago
Verdict
Headline takes no side. We score IVA +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Inventiva has secured up to €130 million in financing from Claret Capital Partners and BlackRock to support the Phase 3 development of lanifibranor.
So whatSecuring significant capital from major institutional investors reduces funding risk and provides the runway necessary to reach critical clinical milestones.
More positive than 91% of claims this week
The top-line Phase 3 readout for the NATiV3 trial, evaluating lanifibranor for MASH treatment, is anticipated in Q4 2026.
So whatThis establishes a specific, high-volatility catalyst date that will determine the drug's viability and the company's valuation.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 77% of claims this week
Inventiva is utilizing a combined strategy of debt and equity financing to optimize its capital structure.
More positive than 55% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company secured €130m in financing to support critical Phase 3 development of its MASH therapy.
More positive than 54% of ticker scores this week
Mentioned as a recent late-stage biotech investment by Claret Capital Partners.
More positive than 48% of ticker scores this week
BlackRock is mentioned as a participant in the financing round for Inventiva.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
4h ago
+2.7%
Price agrees with the score
$3.86 vs $3.76 close before publication (Jun 15) · not market-adjusted
IVA chart →
